

ESMO PRECEPTORSHIP PROGRAMME ENDOMETRIAL CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
10-11 July 2025

CO-CHAIRS

Ilaria Colombo, Switzerland
Isabelle L. Ray-Coquard, France

SPEAKERS

Jalid Sehoul, Germany
Jean Emmanuel Kurtz, France
Toon van Gorp, Belgium
Frédéric Amant, Belgium
Isabelle Treilleux, France
Nicoletta Colombo, Italy
Frederik Marmé, Germany

LEARNING OBJECTIVES

- To learn about the fundamentals of diagnosis and staging of endometrial cancer
- To understand the importance of pathological and molecular characterization of endometrial cancer
- To understand the multidisciplinary treatment of endometrial cancer
- To learn about the recent advances in the systemic treatment of endometrial cancer and how to implement them in clinical practice
- To learn about novel targets and agents under investigation in endometrial cancer
- To learn the principles of diagnosis and treatment of uterine sarcoma

ACCREDITATION

The programme of this event will be accredited with **ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](https://www.esmo.org).

Thursday, 10 July 2025

09:00-09:15 15'	Welcome and introduction	Ilaria Colombo, CH Isabelle L. Ray-Coquard, FR
09:15-10:30 75'	SESSION 1 Diagnosis and pathology of endometrial cancer	Chairs: Frederik Marmé, DE Nicoletta Colombo, IT
30'	Pathology and molecular classification of endometrial cancer	Isabelle Treilleux, FR
30'	The new FIGO staging 2023	Jalid Sehoul, DE
15'	Q&A	All
10:30-11:00	Coffee break	

11:00-13:15 135'	SESSION 2 Treatment of disease limited to the uterus	Chairs: Jalid Sehouli, DE Isabelle Treilleux, FR
20'	Complex questions for surgery for newly diagnosed endometrial cancer including role of SLN	Frederik Amant, BE
25'	Adjuvant treatment: Who, when and what? (systemic therapy and radiotherapy)	Nicoletta Colombo, IT
15'	Q&A	All
75'	Participants clinical case discussion (5x15')	Faculty
13:15-14:15	Lunch	
14:15-16:15 120'	SESSION 3 Treatment of recurrent-metastatic endometrial cancer – Part 1	Chairs: Jean Emmanuel Kurtz, FR Isabelle L. Ray-Coquard, FR
20'	The revolution of immunotherapy in endometrial cancer	Frederik Marmé, DE
20'	Combinations of anti-PD-(L)1 and chemotherapy or TKI (including PARP)	Nicoletta Colombo, IT
20'	Predictive biomarkers in endometrial cancer	Toon van Gorp, BE
15'	Q&A	All
45'	Participants clinical case discussion (3x15')	Faculty
16:15-16:45	Coffee break	
16:45-18:15 90'	SESSION 4 Treatment of recurrent-metastatic endometrial cancer – Part 2	Chairs: Ilaria Colombo, CH Frederik Amant, BE
20'	PRO and QoL: How to manage	Jean Emmanuel Kurtz, FR
20'	New agents on the horizon: ADC and beyond	Toon van Gorp, BE
20'	Management of immune-related and TKI toxicities	Ilaria Colombo, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
19:30	Dinner	

Friday, 11 July 2025

09:00-10:35 95'	SESSION 5 Special situations	Chairs: Toon van Gorp, BE Nicoletta Colombo, IT
20'	Fertility-sparing approach	Frederik Amant, BE
20'	Rare histological subtypes: Carcinosarcoma	Isabelle L. Ray-Coquard, FR
20'	Hormonal therapy in endometrial cancer: Single agent or combination?	Ilaria Colombo, CH
20'	How to manage old and frail patients?	Jean Emmanuel Kurtz, FR
15'	Q&A	All

10:35-11:05	Coffee break	
11:05-12:35 90'	SESSION 6 Uterine sarcoma	Chairs: Frederik Marmé, DE Isabelle L. Ray-Coquard, FR
20'	Pathology of uterine sarcoma	Isabelle Treilleux, FR
20'	Diagnosis and surgical treatment of uterine sarcoma	Jalid Sehouli, DE
20'	Systemic treatment of uterine sarcoma	Isabelle L. Ray-Coquard, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
12:35-12:50 15'	Conclusion and farewell	Ilaria Colombo, CH Isabelle L. Ray-Coquard, FR
12:50-13:50	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion